With all the technological developments that take place regularly in other industries, it is exciting to see some major advancements being made in the R&D departments of companies focused on reproductive health.
OvaScience™- R&D on AUGMENT, a product that “allows the woman to use her own cellular energy to revitalize the egg”. The company just recently closed on a $37 Million “Series-B” round of funding. http://www.ovascience.com/
Auxogyn™- A company focusing on improving early embryo viability with their cutting edge software. Read all about their exciting progress on their webpage: http://www.auxogyn.com/assets/press-releases/2012-02-02.Financing-Series-A.pdf
Celmatix™- Focuses on diagnostic tools to improve reproductive health. The company raised an additional $1.5 Million in funding in March 2012, http://celmatix.com/wp-content/uploads/2012/03/CelmatixPressRelease8March2012.pdf.
Ib2C™- (Us!!) Secured $4.5 Million in “Series-A” funding in December 2011. Intimate Bridge to Conception, Inc. (Ib2C™) is an early-stage direct to consumer medical device company focused on reproductive health to aid in natural fertility and conception in the privacy of the patient’s home. www.intimatebridge2conception.com
I don’t know about you, but it looks to me like the future R&D in our reproductive health is looking bright.